Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of MichiganNuminus Wellness Reaches Major Milestone With MAPS Sponsored MDMA StudyNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSDPsyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical TrialTryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary FormulationsPsyched Wellness Commences Next Pre-Clinical Study on AME-1Atai Life Sciences Is Setting The Standard For Psychedelic Drug Development

3 Psychedelic Sector Leaders That Investors Need To Be Aware Of

Jan 19, 2021 • 11:02 AM EST
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

The last few years have been significant for the psychedelic therapy industry and we believe the sector is in not even in the first inning of a major growth cycle.

From a regulatory standpoint, the psychedelic therapy industry has reported significant advancements, and this is a trend that we expect to continue. Initially, a few select cities in the US announced the decriminalization of psychedelics. Now, we are seeing states and countries announce pro-psychedelic legislation and believe that our readers need to be aware of this.

While the psychedelic industry has distinct differences from the cannabis industry, we see a lot of similarities from a legalization standpoint. If the psychedelic industry follows the path of the cannabis industry, then we could be looking at the next major emerging market and have been closely following the companies that are levered to the industry.

Today, we want to highlight three companies that are considered to be leaders in the psychedelic therapy industry. These operators are conducting late-stage Food and Drug Administration (FDA) clinical trials and we believe that positive data could prove to be the catalyst that the industry needs to gain more legitimacy.

  1. ATAI Life Sciences is considered to be one of the best private psychedelic therapy companies and is an operator that we are bullish on. The company has been able to tap the capital markets to raise capital and has one of the strongest balance sheets in the sector. ATAI Life Sciences was structured to acquire, incubate and develop psychedelics and other drugs that can be used to treat depression, anxiety, addiction and other mental health conditions. When the company goes public, it expects to be valued between $1 and $2 billion and this is an opportunity to be aware of.
  2. Cybin Corp. (CYBN: NEO) complete a go public transaction in late 2019 and is an operator that we are closely following. The psychedelic therapy company is conducting Phase 2a/2b clinical trials in Jamaica and positive data could prove to be a major catalyst for growth. Cybin is initially focused on developing a treatment for major depressive disorder (MDD) and we will be monitoring how the story advances from here.
  3. Wake Network is another private company that is focused on the psychedelic therapy market and is expected to go public in the near future. From intellectual property to human capital, the company has recently reported several major developments and this is an opportunity that we are closely following. One of the ways that Wake Network has been able to differentiate itself is through the development of a regenerative feedback loop that allows it to research, monitor and incorporate results from clinical studies to personalize medicine which should reduce the level of ambiguous results from traditional medicine. We expect the company to go public with a valuation that is substantially lower than ATAI and will monitor how the story advances.
Share Share - Facebook Share - Twitter


Authored By

Michael Berger


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.